Provided by Tiger Trade Technology Pte. Ltd.

Cue Biopharma, Inc.

23.98
-0.6300-2.56%
Post-market: 24.400.4200+1.75%19:30 EDT
Volume:177.75K
Turnover:4.28M
Market Cap:174.20M
PE:-0.81
High:26.00
Open:25.55
Low:23.24
Close:24.61
52wk High:45.50
52wk Low:4.97
Shares:7.26M
Float Shares:6.81M
Volume Ratio:0.84
T/O Rate:2.61%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-29.4600
EPS(LYR):-8.4244
ROE:-1603.48%
ROA:-172.66%
PB:75.41
PE(LYR):-2.85

Loading ...

Company Profile

Company Name:
Cue Biopharma, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
29
Office Location:
40 Guest Street,Boston,Massachusetts,United States
Zip Code:
02135
Fax:
- -
Introduction:
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Pasha Sarraf
Chairman and Director
Shao Lee Lin
President and Chief Executive Officer and Director
Daniel Camardo
Director
Pamela D. Garzone
Director
Viola Meehan
Director

Shareholders

Name
Position
Shao Lee Lin
President and Chief Executive Officer and Director
Colin G. Sandercock
Senior Vice President, Intellectual Property
Daniel G. Baker
Interim Chief Development Officer
Michael Meluzio
Principal Accounting Officer and Vice President
Sumita Ray
Chief Legal & Compliance Officer and Corporate Secretary